|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
Q1 FY2023
As of Mar 31, 2023
|
Q4 FY2022
As of Dec 31, 2022
|
Q3 FY2022
As of Sep 30, 2022
|
Q2 FY2022
As of Jun 30, 2022
|
Q1 FY2022
As of Mar 31, 2022
|
Q4 FY2021
As of Dec 31, 2021
|
Q3 FY2021
As of Sep 30, 2021
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ASSETS | ||||||||||||||
| Current assets: | ||||||||||||||
| Cash and cash equivalents | ||||||||||||||
| Total cash and cash equivalents | ||||||||||||||
| Accounts receivable, net | ||||||||||||||
| Total accounts receivable, net | ||||||||||||||
| Prepaid expenses | ||||||||||||||
| Other current assets | ||||||||||||||
| Total current assets | ||||||||||||||
| Notes receivable, net | ||||||||||||||
| Property, equipment, and software, net | ||||||||||||||
| Total property, equipment, and software, net | ||||||||||||||
| Right-of-use-assets, net | ||||||||||||||
| Other assets | ||||||||||||||
| Total other assets | ||||||||||||||
| Total assets | ||||||||||||||
| LIABILITIES AND STOCKHOLDERS' EQUITY | ||||||||||||||
| Liabilities | ||||||||||||||
| Current liabilities: | ||||||||||||||
| Accounts payable | ||||||||||||||
| Total accounts payable | ||||||||||||||
| Accrued expenses and other current liabilities | ||||||||||||||
| Total accrued expenses and other current liabilities | ||||||||||||||
| Current portion of lease liabilities | ||||||||||||||
| Total current liabilities | ||||||||||||||
| Lease liabilities, net of current portion | ||||||||||||||
| Other non-current liabilities | ||||||||||||||
| Total other non-current liabilities | ||||||||||||||
| Total liabilities | ||||||||||||||
| Stockholders' equity: | ||||||||||||||
| Common stock | ||||||||||||||
| Common Class A | ||||||||||||||
| Common Class B | ||||||||||||||
| Additional paid-in capital | ||||||||||||||
| Accumulated deficit | ||||||||||||||
| Accumulated other comprehensive loss | ||||||||||||||
| Total accumulated other comprehensive loss | ||||||||||||||
| Total stockholders' equity attributable to Enfusion, Inc. | ||||||||||||||
| Non-controlling interests | ||||||||||||||
| Total stockholders' equity | ||||||||||||||
| Total liabilities and stockholders' equity | ||||||||||||||
Loading...